Latest Ratios: P/E Ratio 7.9x · EV/EBITDA 18.4x · ROE 59.9%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $2.2B | $1.3B | $1.3B | $613M | $3.0B | $1.6B | $1.9B | $578M | $349M | $74M |
| Enterprise Value | $2.1B | $2.2B | $1.3B | $1.3B | $527M | $2.7B | $1.4B | $1.6B | $460M | $183M | $34M |
| P/E Ratio → | 7.92 | 7.71 | 228.50 | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.45 | 7.82 | 5.58 | 7.34 | 4.57 | 64.88 | 32.69 | 5926.62 | 1248.84 | 829.94 | 428.32 |
| P/B Ratio | 3.91 | 3.81 | 3.48 | 3.41 | 1.51 | 6.18 | 4.02 | 6.31 | 5.14 | 2.10 | 2.06 |
| P/FCF | 15.58 | 16.34 | 29.76 | — | — | — | — | — | — | — | — |
| P/OCF | 15.55 | 16.31 | 29.58 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.80 | 5.57 | 7.61 | 3.93 | 59.98 | 27.43 | 4964.30 | 994.05 | 435.58 | 199.13 |
| EV / EBITDA | 18.42 | 19.33 | 88.68 | — | — | — | — | — | — | — | — |
| EV / EBIT | 20.05 | 18.63 | 106.55 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 16.30 | 29.67 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | -8837.8% | 99.8% | 97.7% |
| Operating Margin | 37.1% | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -12129.2% | -11205.5% | -13187.3% |
| Net Profit Margin | 101.5% | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -13848.8% | -16855.2% | -13465.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 59.9% | 1.5% | -19.9% | -24.5% | -40.8% | -29.1% | -43.0% | -46.1% | -70.2% | -83.3% |
| ROA | 44.1% | 44.1% | 1.0% | -15.3% | -21.3% | -35.9% | -26.1% | -37.6% | -38.2% | -57.4% | -51.4% |
| ROIC | 16.6% | 16.6% | -0.9% | -18.4% | -29.1% | -67.8% | -114.7% | — | — | — | -325.7% |
| ROCE | 18.9% | 18.9% | -1.0% | -20.5% | -24.0% | -38.7% | -28.0% | -40.3% | -35.1% | -40.8% | -57.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.21 | 0.26 | 0.02 | 0.02 | 0.02 | — | — | — | — |
| Debt / EBITDA | 0.66 | 0.66 | 5.38 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.01 | 0.13 | -0.21 | -0.47 | -0.65 | -1.02 | -1.05 | -1.00 | -1.10 |
| Net Debt / EBITDA | -0.05 | -0.05 | -0.28 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.04 | -0.09 | — | — | — | — | — | — | — | — |
| Interest Coverage | 27.36 | 27.36 | 2.54 | -26.92 | — | — | — | — | — | — | — |
Net cash position: cash ($80M) exceeds total debt ($75M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.25 | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
| Quick Ratio | 4.76 | 4.76 | 4.17 | 4.99 | 9.06 | 12.15 | 12.67 | 27.90 | 18.30 | 21.52 | 5.22 |
| Cash Ratio | 4.25 | 4.25 | 3.67 | 4.54 | 8.45 | 11.47 | 12.45 | 27.09 | 17.33 | 21.28 | 5.00 |
| Asset Turnover | — | 0.38 | 0.43 | 0.32 | 0.28 | 0.08 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.71 | 0.71 | 0.72 | 0.36 | 0.23 | 0.06 | — | — | — | — | — |
| Days Sales Outstanding | — | 53.45 | 56.73 | 50.10 | 36.72 | 123.37 | — | 422.39 | 171.07 | 94.73 | 181.45 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.6% | 13.0% | 0.4% | — | — | — | — | — | — | — | — |
| FCF Yield | 6.4% | 6.1% | 3.4% | — | — | — | — | — | — | — | — |
| Buyback Yield | 4.7% | 4.4% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.7% | 4.4% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $139M | $146M | $143M | $142M | $129M | $118M | $93M | $85M | $77M | $35M |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AUPH stock.
Aurinia Pharmaceuticals Inc.'s current P/E ratio is 7.9x. The historical average is 7.7x. This places it at the 100th percentile of its historical range.
Aurinia Pharmaceuticals Inc.'s current EV/EBITDA is 18.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 54.0x.
Aurinia Pharmaceuticals Inc.'s return on equity (ROE) is 59.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -65.6%.
Based on historical data, Aurinia Pharmaceuticals Inc. is trading at a P/E of 7.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aurinia Pharmaceuticals Inc. has 88.5% gross margin and 37.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Aurinia Pharmaceuticals Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Single product concentration risk
Metrics are mathematically derived from official filings.
Margin Expansion Reflects Operating Leverage
According to reported financials, AUPH's gross margin reached 92.1% in 2026Q2, up from 84.6% in 2024Q1, while operating margin surged to 55.7%, indicating significant scale benefits and cost discipline.
The gross margin improvement from 84.6% to 92.1% over ten quarters suggests manufacturing efficiencies and fixed-cost absorption are driving profitability, as per the ratio data. Operating margin's leap from -21.3% in 2024Q1 to 55.7% in 2026Q2 underscores operating leverage, with SG&A as a percentage of revenue declining sharply. However, the 2025Q4 net margin of 2.7% was distorted by a one-time tax benefit, so investors should focus on operating margin as the cleaner measure of earning power.
ROIC Inflects from Negative to Positive
Based on EDBL's reported figures, ROIC improved from -2.0% in 2024Q1 to 6.4% in 2026Q2, signaling a transition from value destruction to value creation, though returns remain modest relative to cost of capital.
The ROIC trajectory shows a clear inflection, with negative returns in early 2024 turning positive by mid-2024 and stabilizing around 5-6% in 2026. This improvement is driven by margin expansion rather than asset efficiency, as asset turnover remains low at 0.11. The 2025Q4 ROE spike to 44.5% is an anomaly due to the one-time tax benefit, masking the underlying ROE of approximately 6%, which is more representative of sustainable return generation.
Working Capital Drag from Inventory Buildup
As reported in financial statements, AUPH's cash conversion cycle lengthened to 654 days in 2026Q2 from 456 days in 2024Q1, driven by inventory days soaring to 636, indicating potential overstocking or slow-moving product.
The CCC expansion is primarily due to DIO increasing from 466 days in 2024Q1 to 636 days in 2026Q2, which may indicate inventory management challenges or strategic stockpiling. DSO has remained relatively stable around 43-56 days, while DPO has been volatile, dropping from 117 days in 2024Q4 to 31 days in 2026Q2, suggesting reduced supplier leverage. This working capital drag partially offsets the strong cash flow generation, and investors should monitor whether inventory levels normalize or signal demand issues.
Deleveraging Strengthens Balance Sheet
According to recent SEC filings, AUPH's D/E ratio fell from 0.25 in 2024Q1 to 0.10 in 2026Q2, while interest coverage improved to 52.46, indicating a comfortable debt position with ample earnings to service obligations.
The consistent deleveraging trend, with total debt declining from $88.5M to $60.4M, reflects a deliberate strategy to reduce financial risk, as per balance sheet data. Interest coverage of 52.46 in 2026Q2 is exceptionally strong, providing a substantial cushion against earnings volatility. The D/EBITDA ratio of 1.18 is low, suggesting that debt is well-covered by EBITDA, though the company's reliance on a single product for cash flows warrants monitoring for any competitive threats.
Ample Liquidity Buffer Supports Operations
Based on reported figures, AUPH's current ratio stands at 5.42 in 2026Q2, with quick ratio at 4.97, indicating a robust liquidity position that can withstand operational shocks and fund growth initiatives.
The current ratio has remained consistently above 5.0 over the past ten quarters, reflecting a strong cash position and minimal short-term obligations. Cash of $179.8M covers over 2.5x total debt, providing a significant buffer against adverse events. However, the high inventory days suggest that a portion of current assets is tied up in stock, which could be a drag on liquidity if demand falters, though the quick ratio of 4.97 mitigates this concern.
Misapplied P/E Obscures Earnings Quality
The trailing P/E of 7.81 is misleading for AUPH because it includes a one-time tax benefit in 2025Q4, understating the true earnings multiple; forward P/E of 16.84 better reflects ongoing profitability.
Investors commonly use P/E to gauge valuation, but for AUPH, the trailing P/E is distorted by the non-recurring tax benefit that inflated 2025Q4 net income. Excluding that benefit, the underlying P/E would be significantly higher, making the stock appear cheaper than it is. Instead, EV/EBITDA of 18.16 or P/FCF of 15.36 provide cleaner valuation metrics, as they are less affected by one-time items and better capture the company's cash-generating ability. This misapplication could lead to incorrect investment decisions if not adjusted for earnings quality.